Fuzheng Huayu Tablets

DRUG3 trials

Sponsors

Shanghai University of Traditional Chinese Medicine, Zhiyun Yang, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Conditions

Decompensated Hepatitis B CirrhosisMetabolic Dysfunction-associated Fatty Liver CirrhosisPosthepatitic Cirrhosis

Phase 4

Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis

CompletedNCT00543426

Shanghai University of Traditional Chinese MedicinePosthepatitic Cirrhosis

Start: 2007-09-30End: 2009-06-30Updated: 2013-03-07

Fuzheng Huayu Tablets for Metabolic Dysfunction-Associated Fatty Liver Cirrhosis (Compensated): A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study

Not yet recruitingNCT07663643

Xinhua Hospital, Shanghai Jiao Tong University School of MedicineMetabolic Dysfunction-associated Fatty Liver Cirrhosis

Start: 2026-05-25End: 2029-04-02Target: 459Updated: 2026-06-23

Unknown Phase

Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

Not yet recruitingNCT07017426

Zhiyun YangDecompensated Hepatitis B Cirrhosis

Start: 2025-07-01End: 2027-07-01Target: 432Updated: 2025-06-12

Related Papers

Fuzheng Huayu tablets reduces the risk of further decompensation after the first decompensation in patients with HBV-related cirrhosis: protocol for a randomized, double-blind, placebo-controlled, multicenter trial

Frontiers in Pharmacology2026-07-02